BIIB
Evidence as of 2026-09-02Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
−0.3 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
Mixed (-0.2 of a possible +2; was -0.2 before debate) · confidence high. For the fiscal quarter ended 2026-04-27 (Q1 2026) reported revenue was $ 2,477,800,000 with net income $ 319,500,000 (≈ 12.9% net margin) and diluted EPS $ 2.15. Earlier quarters show revenue of $ 2,645,500,000 in the fiscal quarter ended 2025-07-29 (Q2 2025) with net income $ 634,800,000 (≈ 24.0% margin, EPS $ 4.33), $ 2,534,700,000 in the fiscal quarter ended 2025-10-29 (Q3 2025) with net income $ 466,500,000 (≈ 18.4%, EPS $ 3.17), and $ 2,431,000,000 in the fiscal quarter ended 2025-04-30 (Q1 2025) with net income $ 240,500,000 (≈ 9.9%, EPS $ 1.64).
Shares outstanding rose gradually from 145,661,642 as of 2024-07-31 to 147,637,117 as of 2026-04-27 (≈ 1.98 million increase). Long-term debt increased from $ 4,547,200,000 as of 2024-12-31 to $ 6,286,800,000 as of 2025-12-31 and $ 6,288,500,000 as of 2026-03-31, while total assets moved from $ 28,049,300,000 (2024-12-31) to $ 29,483,100,000 (2026-03-31) and liabilities from $ 11,333,300,000 to $ 10,831,400,000 over the same span. Trailing twelve‑month metrics show FCF $ 1,712,500,000, EPS (TTM) $ 11.29, FCF/share ≈ $ 11.5398, EBITDA (TTM) $ 3,511,700,000 and operating income (TTM) $ 2,864,300,000. The packet also records a single ETF holding snapshot: BIIB weight 0.05% in IVV at the timestamp provided.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Reported revenues for single fiscal quarters: Q1 2026 (2026-01-01 to 2026-03-31) = $2,477,800,000; Q3 2025 (2025-07-01 to 2025-09-30) = $2,534,700,000; Q2 2025 (2025-04-01 to 2025-06-30) = $2,645,500,000; Q1 2025 (2025-01-01 to 2025-03-31) = $2,431,000,000.
XBRL companyfacts · 0000875045-26-000045Net income (single fiscal quarters) and implied quarterly net margin (net income divided by that quarter's revenue): Q1 2026 net income $319,500,000 (319.5 / 2,477.8 ≈ 12.9%); Q2 2025 net income $634,800,000 (634.8 / 2,645.5 ≈ 24.0%); Q3 2025 net income $466,500,000 (466.5 / 2,534.7 ≈ 18.4%); Q1 2025 net income $240,500,000 (240.5 / 2,431.0 ≈ 9.9%).
XBRL companyfacts · 0000875045-26-000045Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Nothing in this slice of the evidence rose to a claim — a quiet read, which itself is information.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
No computed signal history for this symbol yet — signals need roughly 70 trading days of price history.
Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02T13:45:47.228469+00:00, Biogen Inc. (BIIB) is a holding in the IVV ETF with a weight of 0.05% of the fund.
ETF constituents · market dataThe provided evidence contains a single ETF membership record for BIIB (the IVV holding shown at the timestamp 2026-09-02T13:45:47.228469+00:00).
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
News coverage reports that Biogen completed its acquisition of RayThera on August 6, and notes RayThera's lead program entered Phase 1 trials in July 2026; the story also references Biogen posting a second-quarter beat just over a week before the deal was announced.
News · finance.yahoo.com · 2026-09-02Multiple outlets carried a Biogen-linked announcement about presentations of clinical data for zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Epilepsy Congress (EEC).
News · globenewswire.com · 2026-09-01Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
Free cash flow (TTM) is $1,712,500,000.
Valuation inputs · SEC XBRL + stored EOD closeEarnings per share (TTM) is $11.29.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
The evidence set supports a favorable read because Biogen shows strong cash-generation and profitability metrics (TTM FCF $1.71B; TTM EPS $11.29; TTM EBITDA $3.51B and operating income $2.86B) alongside positive clinical and corporate news flow (sustained zorevunersen OLE data coverage and completion of the RayThera acquisition with a Phase 1 program). Multiple sell-side actions skew toward buy/upgrade in the provided consensus snapshot, which aligns with syndicated positive publicity and a recent intraday share response noted by coverage. While some quarterly net income and EPS values fluctuate, the TTM and per-share cash-flow figures indicate material cash generation ability; asset growth and reported cash provide context to the reported rise in long-term debt. Evidence strength: financial statement items and share/debt point-in-time figures are directly sourced to SEC filings (high strength); valuation aggregates (TTM FCF, EPS, EBITDA) are computed from provided data (moderate-high strength); news items are widely syndicated reporting (moderate strength).
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.37
20 surviving claims rest on 9 distinct sources; the heaviest analyst carries 30% of them, and 98% of what the desk raised survived the debate.
The read rests on a modestly diverse base: 20 surviving claims draw from nine distinct sources, so the evidence is not purely single-source but has some source-concentration. The fact one analyst supplied nearly a third of the surviving claims and 98% of suggested issues survived the desk debate implies high internal consistency but also a risk of analyst- or process-driven confirmation — treat the package as informative but potentially brittle around the dominant contributor's inputs.
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
16 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer−0.5 to the score
1 holdings record
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.0 to the score
7 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on BIIB Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.